Home>Topics>Stocks>Abiomed

Abiomed ABMD

  1. All
  2. Commentary
  3. Headlines
    1. Jackson Square Partners reports 12% passive stake in Abiomed

      Headlines

      Fri, 10 Oct 2014

      Link to filing Post your comment!

    2. Update: Abiomed Announces Clinical Trial Results For Impella RP

      Headlines

      Fri, 19 Sep 2014

      By Andy Batts : Abiomed (NASDAQ: ABMD ) announced RECOVER RIGHT clinical trial results earlier this ..... 73% in the overall patient population. Michael R. Minogue, Abiomed 's Chairman, President and CEO, said, "The Impella RP is

    3. A Young Power Couple's Kickstart Portfolio

      Headlines

      Fri, 6 Jun 2014

      Holding Market Value ($) Weight (%) Star Rating Matt's Roth IRA: Cash 5,263 1.96 N/A Matt's Roth IRA: Abiomed ABMD 184 0.07 N/A Matt's Roth IRA: Alpine Dynamic Dividend AOD 1,134 0.42 Matt's Roth IRA: Biomarin Pharmaceuticals

    4. Dropping Coverage of Abiomed

      Commentary

      Wed, 18 Dec 2013

      We are no longer providing equity research on Abiomed . We provide broad coverage of more than 1,800 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.

    5. Abiomed Back on Track in 2Q, Following Weak Beginning of Fiscal Year

      Commentary

      Wed, 13 Nov 2013

      Abiomed reported strong fiscal second-quarter ..... largely consistent with our expectations. Abiomed remains on track to reach our full-year ..... continues to grow, which supports our view of Abiomed 's positive moat trend. We think there

    6. Abiomed Posts Weak First Quarter, but Our Fair Value Estimate Is Unchanged

      Commentary

      Thu, 1 Aug 2013

      Abiomed reported fiscal first-quarter performance ..... variance from quarter to quarter, we think Abiomed can still reach our full-year projections ..... nascent stage of the acute VAD market that Abiomed is still pioneering, we do not think the

    7. Thoratec Delivers Strong 2Q Following Anemic 1Q

      Commentary

      Thu, 1 Aug 2013

      unlikely to reach commercialization before 2017. Even though it will be several years before the PHP product is marketable, it nonetheless provides Thoratec with important entree to the acute VAD niche that is currently dominated by Abiomed .

    8. Abiomed Sales Rise Past Estimates

      Commentary

      Wed, 17 Apr 2013

      On Wednesday, Abiomed ABMD released preliminary fourth-quarter ..... our positive moat trend rating for Abiomed . Although we do not believe the firm ..... yet, momentum continues to build for Abiomed with the U.S. release of Impella

    9. Abiomed Meets Expectations in 3Q

      Commentary

      Wed, 6 Feb 2013

      turbulence on the regulatory front, Abiomed ABMD remained on track operationally ..... set as the CP gains traction in Abiomed 's key geographic market during ..... the quarter (19% of sales), Abiomed maintains a healthy financial position

    10. FDA Panel Recommends Device Classification That Changes Regulatory Pathway for Abiomed's Impella

      Commentary

      Fri, 7 Dec 2012

      trim our fair value estimate for Abiomed ABMD to $17 per share from $18. Because ..... increase the cost of doing business for Abiomed and any other firm that wants to ..... device, meaning some didn't think Abiomed should be forced to collect additional

    « Prev12345Next »
    Content Partners